Kevin Strange, CFO of Cala Health, is a proven medical device executive with broad functional and sector experience. Prior to joining Cala, Kevin was CFO of Inari Medical until its acquisition by Stryker Corporation in 2025 for nearly $5B. Prior to Inari, Kevin worked in Business Development and Strategy at Boston Scientific and as a sell-side equity research analyst at Wells Fargo Securities and Bank of America Merrill Lynch covering the MedTech sector. Kevin started his career in medical devices in the Cardiac Rhythm Management division of Medtronic. Kevin holds a BS in Biology from Davidson College and an MBA from New York University’s Stern School of Business.